{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:11:20Z","timestamp":1789996280229,"version":"4.0.1"},"reference-count":40,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>While typically associated with benign infectious mononucleosis, Epstein\u2013Barr virus (EBV) is now recognized as a pivotal driver of complex immunopathological disorders. By shuttling between lytic replication and strategic latency programs, EBV reprograms B-cell biology to evade immune surveillance and disrupt homeostasis. Central to this pathogenesis is the viral protein EBNA1, which triggers autoimmunity through molecular mimicry with host antigens, including GlialCAM in multiple sclerosis (MS), keratin in rheumatoid arthritis, and nuclear proteins in systemic lupus erythematosus. These autoimmune responses are further exacerbated by bystander activation and epitope spreading, fueling chronic inflammation in Crohn\u2019s disease, type 1 diabetes, and IgA nephropathy. EBV can also promote the development of lymphoproliferative disorders, whether in immunocompetent hosts or in the context of immunosuppression; however, the emergence of EBV-positive forms within diseases that are usually EBV-negative is closely linked to an underlying state of immunosuppression. Distinct from these chronic states, EBV-associated hemophagocytic lymphohistiocytosis (HLH) represents a critical hyperinflammatory emergency in which defective cytotoxicity leads to an uncontrolled T-cell- or NK-cell-driven cytokine storm; together with chronic active EBV disease (CAEBV), HLH disproportionately affects children, and both receive particular attention in this review. More recently, emerging but not yet consolidated evidence has also suggested a possible association between EBV reactivation and long COVID. Elucidating these diverse molecular interactions is essential for developing the next generation of targeted therapies and vaccine strategies aimed at mitigating the systemic impact of this virus.<\/jats:p>","DOI":"10.3390\/v18091048","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:50:03Z","timestamp":1789995003000},"page":"1048","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epstein\u2013Barr Virus: More than Just an Infection"],"prefix":"10.3390","volume":"18","author":[{"given":"Evelyn","family":"Van de Perre","sequence":"first","affiliation":[{"name":"Faculty of Medicine, UCLouvain, 59 Promenade de l\u2019Alma, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieuc","family":"Van Nieuwenhuyse","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UCLouvain, 10 Avenue Hippocrate, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-2346","authenticated-orcid":false,"given":"Jean Cyr","family":"Yombi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UCLouvain, 10 Avenue Hippocrate, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Yu, H., and Robertson, E.S. (2023). Epstein\u2013Barr Virus History and Pathogenesis. Viruses, 15.","DOI":"10.3390\/v15030714"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fugl, A., and Andersen, C.L. (2019). Epstein-Barr virus and its association with disease\u2014A review of relevance to general practice. BMC Fam. Pract., 20.","DOI":"10.1186\/s12875-019-0954-3"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Morawiec, N., Adamczyk, B., Spyra, A., Herba, M., Boczek, S., Korbel, N., Polecho\u0144ski, P., and Adamczyk-Sowa, M. (2025). The Role of Epstein-Barr Virus in the Pathogenesis of Autoimmune Diseases. Medicina, 61.","DOI":"10.3390\/medicina61071148"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e200460","DOI":"10.1212\/NXI.0000000000200460","article-title":"Epstein-Barr Virus in Multiple Sclerosis: Past, Present, and Future","volume":"12","author":"Wahbeh","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Marsh, R.A. (2018). Epstein-Barr Virus and Hemophagocytic Lymphohistiocytosis. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01902"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/qjmed\/hcaa011","article-title":"Adult haemophagocytic lymphohistiocytosis: Review","volume":"115","author":"Yildiz","year":"2022","journal-title":"QJM"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.path.2023.01.008","article-title":"Immunodeficiency-associated Epstein-Barr virus-positive B-cell lymphoproliferative disorders: A review and new paradigm","volume":"16","author":"Chapman","year":"2023","journal-title":"Surg. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gold, J.E., Okyay, R.A., Licht, W.E., and Hurley, D.J. (2021). Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens, 10.","DOI":"10.3390\/pathogens10060763"},{"key":"ref_9","first-page":"79","article-title":"Post-transplant lymphoproliferative diseases: Polish Lymphoma Research Group 2025 recommendations for diagnosis and treatment","volume":"56","author":"Giebel","year":"2025","journal-title":"Acta Haematol. Pol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood.2025032277","article-title":"Chronic active Epstein-Barr virus disease: Molecular pathogenesis, evolving concepts, and emerging therapies","volume":"147","author":"Kimura","year":"2026","journal-title":"Blood"},{"key":"ref_11","unstructured":"International Agency for Research on Cancer (IARC), and World Health Organization (2026, September 14). Nasopharynx: Global Cancer Observatory (GLOBOCAN) 2022 Fact Sheet. Available online: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/4-nasopharynx-fact-sheet.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cgh.2022.07.042","article-title":"Estimating the Global Burden of Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis","volume":"21","author":"Hirabayashi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","first-page":"2533","article-title":"Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells","volume":"5","author":"Lupton","year":"1985","journal-title":"Mol. Cell. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"438204","DOI":"10.6064\/2012\/438204","article-title":"The Epstein-Barr virus EBNA1 protein","volume":"2012","author":"Frappier","year":"2012","journal-title":"Scientifica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.7150\/thno.26823","article-title":"EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eaau5612","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-based design of small molecule inhibitors of Epstein-Barr virus EBNA1 DNA binding","volume":"11","author":"Messick","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/1078-0432.CCR-24-2814","article-title":"First-in-human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein-Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies","volume":"31","author":"Colevas","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_18","first-page":"376","article-title":"Epstein-Barr virus primary infection in healthy children","volume":"90","year":"2019","journal-title":"An. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rostgaard, K., Balfour, H.H., Jarrett, R., Erikstrup, C., Pedersen, O., Ullum, H., Nielsen, L.P., Voldstedlund, M., and Hjalgrim, H. (2019). Primary Epstein-Barr virus infection with and without infectious mononucleosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226436"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0022-510X(09)70003-6","article-title":"The history of multiple sclerosis: The changing frame of the disease over the centuries","volume":"277","author":"Murray","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rotstein, D.L., Maxwell, C., Tremlett, H., Vyas, M.V., Everett, K., and Marrie, R.A. (2026). Multiple Sclerosis Onset Preceding Epstein-Barr Virus Infection. JAMA Neurol., e262514. Epub ahead of print.","DOI":"10.1001\/jamaneurol.2026.2514"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2026.0240","article-title":"Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases","volume":"83","author":"Vietzen","year":"2026","journal-title":"JAMA Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13345","DOI":"10.1111\/sji.70016","article-title":"The role of Epstein-Barr virus molecular mimicry in various autoimmune diseases","volume":"101","author":"Munir","year":"2025","journal-title":"Scand. J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nour Eddine, H.F., Kassem, A.M., Salhab, Z., Sherri, N., Moghabghab, K., Mohsen, Z., Naim, G., Mahmoud, S., Jurjus, A., and Hashash, J.G. (2025). Toll-like receptor 9 mediates Epstein-Barr virus-aggravated inflammation in a mouse model of inflammatory bowel disease. Biomedicines, 13.","DOI":"10.3390\/biomedicines13071535"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Mestecky, J., Julian, B.A., and Raska, M. (2023). IgA nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1085922"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"eady0210","DOI":"10.1126\/scitranslmed.ady0210","article-title":"Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus","volume":"17","author":"Younis","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41584-024-01167-9","article-title":"Epstein\u2013Barr virus as a potentiator of autoimmune diseases","volume":"20","author":"Robinson","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01621-x","article-title":"Hemophagocytic lymphohistiocytosis: Current treatment advances, emerging targeted therapy and underlying mechanisms","volume":"17","author":"Wu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e30772","DOI":"10.1002\/pbc.30772","article-title":"Prognostic scoring system for pediatric Epstein\u2013Barr virus-associated hemophagocytic lymphohistiocytosis based on baseline characteristics: A multicenter retrospective study","volume":"71","author":"Kong","year":"2024","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s10875-021-01073-9","article-title":"T Cell-Epstein-Barr Virus\u2013Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH","volume":"41","author":"Shamriz","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.17638","article-title":"Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: A complex relationship with diverse origins, expression and outcomes","volume":"196","author":"Curry","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjh.20264","article-title":"Efficacy and safety of ruxolitinib-based regimen in the treatment of paediatric Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis","volume":"207","author":"Wang","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Luniewski, A., Chaudhary, S., Goldfarb, A., and Obiorah, I.E. (2026). EBV-Driven NK\/T-Cell Lymphoproliferative Disorders: Clinical Diversity and Molecular Insights. Lymphatics, 4.","DOI":"10.3390\/lymphatics4010007"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100160","DOI":"10.1016\/j.bneo.2025.100160","article-title":"Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia","volume":"2","author":"Orlando","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_38","unstructured":"European Medicines Agency (EMA) (2026, August 22). Ebvallo, INN-Tabelecleucel: EPAR\u2014Product Information, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ebvallo-epar-product-information_en.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.bneo.2024.100053","article-title":"JAK1\/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: A phase 2 study","volume":"2","author":"Uemura","year":"2025","journal-title":"Blood Neoplasia"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Harada, N., Sonoda, M., Park, S., Ohga, S., Eguchi, K., Adachi, S., Kinoshita, K., Yada, Y., Shiraishi, A., and Ohshima, K. (2026). Long-term outcomes of chronic active Epstein\u2013Barr virus infection in childhood after dominantly infected lymphocyte subpopulation management. J. Infect. Dis., jiag191. Epub ahead of print.","DOI":"10.1093\/infdis\/jiag191"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/1048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:50:43Z","timestamp":1789995043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/1048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["v18091048"],"URL":"https:\/\/doi.org\/10.3390\/v18091048","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}